Expert Interviews
Effective Strategies for Managing Cancer Clinical Trials
In the ever-evolving landscape of clinical trials, the expertise of professionals like Clinical Research Associates (CRAs) and consultants is pivotal in driving successful outcomes. To delve into the intricacies of managing and executing clinical trials, we are excited to interview Ezequiel Senderowicz, a distinguished CRA and Clinical Trials Consultant. Ezequiel offers a wealth of knowledge on the challenges faced in cancer clinical trials, strategies for ensuring compliance and effective monitoring, and insights into the future of clinical research. His experience sheds light on the critical aspects of navigating complex trials and advancing the field through innovation and dedicated oversight. Join us as Ezequiel shares his expertise and valuable perspectives on the dynamic world of clinical trials.
• What are the main challenges you have faced in cancer-related clinical trials, and how have you overcome them?
Ezequiel Senderowicz: The complexity of some projects can be a barrier for sites to feel comfortable with recruitment. In these cases, the best approach is to provide prompt and ongoing support to answer any questions the site may have. When it comes to recruitment, building trust with the person responsible for selecting which studies to prioritize is essential, especially when there are multiple studies for the same indication.
• What special considerations should a CRA have when conducting monitoring visits for cancer clinical trials?
Ezequiel Senderowicz: A CRA must maintain their credibility, as this is crucial to building trust with the site. Humility and accessibility are key, as well as being meticulous with the information provided to the sites.
• What recommendations would you give to ensure compliance with regulations and ethical standards in cancer clinical trials?
Ezequiel Senderowicz: In a cancer trial, there are many important aspects, and it’s challenging for a CRA to have full control during the first visit. That’s why the selection visit is critical, as it allows the training of well-prepared sites that are knowledgeable about regulations and GCP. This helps to ensure the focus is on improving the process rather than constantly fearing a serious breach with every source.
• How do you approach public awareness and education about the importance of participating in cancer clinical trials?
Ezequiel Senderowicz: On a personal level, I actively engage with people around me to help them understand the key aspects and benefits of clinical trials.
Thank you, Ezequiel Senderowicz, for your valuable insights and time today. Your expertise in managing cancer clinical trials and your strategic approach have provided us with a clearer understanding of the field. We appreciate your contributions and wish you continued success in your work. Thank you once again for sharing your perspectives with us.